Dr. Reddy's Laboratories Limited (DRREDDY) — Announcement | 28 July 2026(2 announcements)

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Announcement Neutral 📄 PDF

No summary available

2 Announcement Neutral 📄 PDF
📢 Key Event
Dr. Reddy's reported Q1 FY27 revenue of ₹8,071 crores with a ₹240 crore semaglutide provision and improved underlying margins.
🔄 What Changed
Revenue declined 5.6% YoY to ₹8,071 crores, with EBITDA margin at 12.5% before provision and 15.4% excluding it.
🔮 What's Next
November 2026 target for resuming semaglutide supply; 6-7 million pens planned for November-March; mid-December 2026 US launch target for abatacept; ₹1,800 crores CAPEX for FY27; 20% margin target maintained excluding semaglutide.
💡 Investor Takeaway
The semaglutide API provision is a temporary hit, but underlying business momentum remains strong with margin improvement and key product launches driving future growth.

Dr. Reddy's Laboratories reported a 5.6% YoY revenue decline to ₹8,071 crores in Q1 FY27, driven by lower lenalidomide sales and a ₹240 crore provision for semaglutide API inventory issues, though margins improved excluding this provision. Key updates include successful launches of bosutinib and nintedanib in North America, semaglutide approval in India, and progress on biosimilars and access initiatives, with management maintaining a 20% margin target excluding semaglutide-related impacts.

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

📊 More DRREDDY filings

See all DRREDDY filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DRREDDY — Free

Free account · 2 AI queries/day